Biocryst Pharmaceuticals Inc
BCRX Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 26, 2026
$7.88
KIRA · Stoqly’s AI analyst, in plain words
- Biocryst Pharmaceuticals Inc had $875M of revenue in fiscal 2025, up 94.1% on the year before. Over five years, revenue changed +117.9% a year on average.
- Its operating margin was 39.0%, up 39.5 pts: of every 100 in sales, about 39 is left after running the business.
- Biocryst Pharmaceuticals Inc made $264M of net profit in fiscal 2025.
- Free cash flow was $345M in fiscal 2025, 39.4% of revenue.
- Biocryst Pharmaceuticals Inc has $272M more cash than debt.
Market cap
$2.1B
P/E
—
Revenue
$875M
Net income
$264M
Free cash flow
$345M
Operating margin
39.0%
Biocryst Pharmaceuticals Inc in 30 seconds · fiscal 2025
Are sales growing?
+94.1%
Yes. Sales grew 94.1% last year.
Does it make a profit?
30.2%
Yes. It keeps 30.2% of every sale as profit.
Does profit turn into cash?
39.4%
Yes. 39.4% of sales ends up as free cash.
Is debt under control?
Net cash
Yes. It has more cash than debt.
How healthy are the accounts?
7 / 9
Solid. It passes 7 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Biocryst Pharmaceuticals Inc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Legal name
- BIOCRYST PHARMACEUTICALS INC
- CIK
- 0000882796
Biocryst Pharmaceuticals Inc · BCRX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $157M | $271M | $331M | $451M | $875M |
| Revenue growth | 782.4% | 72.3% | 22.4% | 36.0% | 94.1% |
| Gross margin | 95.4% | 97.6% | 98.6% | 97.3% | 97.8% |
| Operating margin | −113.1% | −54.8% | −31.3% | −0.6% | 39.0% |
| Net income | −$184M | −$247M | −$227M | −$88.9M | $264M |
| Net margin | −117.1% | −91.2% | −68.4% | −19.7% | 30.2% |
| Diluted EPS | −$1.03 | −$1.33 | −$1.18 | −$0.43 | $1.21 |
| Cash | |||||
| Cash from operations | −$142M | −$162M | −$95.1M | −$52.0M | $347M |
| Capital expenditure | $2.4M | $1.4M | $2.2M | $1.1M | $2.5M |
| Free cash flow | −$145M | −$163M | −$97.3M | −$53.1M | $345M |
| FCF margin | −92.0% | −60.3% | −29.4% | −11.8% | 39.4% |
| Share count change | 7.1% | 3.8% | 3.4% | 7.5% | 5.8% |
| Debt and strength | |||||
| Cash and short-term investments | $508M | $424M | $389M | $321M | $275M |
| Debt incl. finance leases | $298M | $234M | $308M | $319M | $2.8M |
| Shareholders' equity | −$107M | −$295M | −$456M | −$476M | −$119M |
| Net debt / EBITDA | — | — | — | — | −0.8x |
| Current ratio | 5.5x | 4.9x | 3.3x | 2.6x | 2.1x |
| Interest coverage | −3.0x | −1.5x | −1.0x | −0.0x | 4.3x |
| Returns and quality | |||||
| Piotroski F-score | 5 | 4 | 4 | 3 | 7 |
| Altman Z'' | −3.7 | −5.9 | −8.1 | −8.8 | −2.6 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$4.1M
4 insiders
Of sales under plans
85%
$3.5M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Biocryst Pharmaceuticals Inc · BCRX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $7.88 a share, the company is worth $2.1B.
Source: SEC EDGAR XBRL filings (CIK 0000882796). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.